Bradycardia may occur during spinal anesthesia with atropine commonly used as a treatment. A 44-year-old female with no known history of any underlying diseases, developed a coronary spasm following ventricular tachycardia when 0.5 mg of atropine was injected intravenously to treat bradycardia during spinal anesthesia. The imbalance caused by atropine in the sympathovagal activity may predispose the coronary artery to develop spasms with ventricular tachycardia. Therefore prudent use of atropine should be accompanied by close monitoring. ( This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Spinal anesthesia has long been considered a relatively safe technique. However, bradycardia may occasionally occur during spinal anesthesia. Sudden and severe bradycardia and asystolic cardiac arrest are considered to be infrequent, but they are certainly the most serious of complications in spinal anesthesia.
Atropine, an anti-muscarinic drug, is commonly used for the treatment of bradyarrythmias.
Thus, we report one such case of a patient experiencing a coronary spasm following ventricular tachycardia (VT) after atropine during spinal anesthesia.
Case Report
A 44-year-old female, height and weight of 158 cm; 53 kg, was scheduled for a varicosectomy and a communicating vein ligation of the bilateral varicose veins.
The patient's family history, past history, obstetric history, and social history were unremarkable.
Upon admission, vital signs were stable with a normal physical examination. The electrocardiogram (ECG) displayed a normal sinus rhythm at 57 beats per minute at normal intervals (Fig. 1) .
The patient's vital signs on arrival to the operation room showed a blood pressure of 134/72 mmHg and heart rate of 90-93 beats/min.
With the patient in the lateral decubitus position, spinal anesthesia was administered using a 25-gauge Quincke-type needle with 12 mg of bupivacaine (Marcaineheavy
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The patient was placed in the supine position for 10 minutes, where the blood pressure lowered to 120/70 mmHg and the heart rate decreased to 82-85 beats/min. The maximal level of the sensory block to cold temperature was T8.
Thereafter, 2.5 mg of midazolam were given intravenously for the sedation and resolution of anxiety.
The patient's blood pressure was then stabilized to 110-90/65-45 mmHg. After one hour since the start of the operation, the patient's heart rate began to gradually decrease. However, since the patient's blood pressure was stable and she was successfully sedated, we decided to observe and no supplementary evaluation of block level was performed. Two hours after the administration of the spinal anesthesia, the heart rate dropped to 42-45 beats/min, and 0.5 mg of atropine was injected intravenously. The patient's heart rate rose to 60 beats per minute within 5 minutes. Shortly after, premature ventricular contraction occurred in the ECG followed by ventricular tachycardia, where the patient's heart rate increased to 140 beats per minute and the blood pressure to 120/60 mmHg ( Fig. 2 and 3 ). The patient complained of chest discomfort, but was capable of communication and cooperation. At that time, the upper sensory block level to cold temperature was T10. The patient was given 10 mg of esmolol intravenously. After 2-3 minutes, the patient's ECG presented an elevation in the ST with a heart rate of 62 beats/min (Fig. 4) . After the termination of the operation, the patient was transferred to the intensive care unit. Laboratory tests at the moment of ventricular tachycardia were nonspecific. The CPK-MB was 19.7 ng/ml; and Troponin I peaked at 6.38 ng/ml, where both subsequently returned back to normal within 2 days. Thyroid function test and fasting lipid Vol. 65, No. 1, July 2013 Atropine IV followed CAS during SA profile were within normal limits.
Coronary angiography (CAG) that was performed after the operation showed luminal stenosis of up to 40% at the middle left anterior descending coronary artery (mLAD), while left circumflex artery (LCX) and right coronary artery (RCA) showed no significant signs of luminal stenosis. Ultrasonic cardiography (UCG) that was performed after the operation showed an ejection fraction of 40%, akinesia at the LCX territory with mild left ventricle (LV) systolic dysfunction, and impaired relaxation. According to the CAG and UCG results that were obtained by the consultation of the department of cardiology, the patient was diagnosed with VT due to vasospasm. After the administration of calcium channel blockers, the patient was discharged 3 days later without any further symptoms.
Discussion
Although spinal anesthesia has long been considered a safe technique, it is known to have several side effects -such as hypo tension, bradycardia, dysrhythmia, nausea and vomiting. Carpenter et al reported that the incidence of bradycardia (heart rate < 60 beats/min) during spinal anesthesia (SA) is 13%, with variables conferring to increased odds of developing bradycardia include a baseline heart rate < 60 beats/min (odds ratio 4.9, P < 0.001), the ASA physical status status classification of 1 versus 3 or 4 (3.5, P < 0.001), current therapy with β-adrenergic blocking drugs (2.9, P < 0.001), and peak block height ≥ T5 (1.7, P = 0.02). Three simple factors (baseline heart rate, ASA physical status, and β-blockade) have a stronger correlation than the peak block 
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height. These findings suggest that the imbalance between the sympathetic and parasympathetic tone may play an important role in the susceptibility to the development of bradycardia during spinal anesthesia [1] . Abrupt, extreme bradycardia and/ or asystolic cardiac arrest during spinal anesthesia seldom occurs, but can be life-threatening when they appear [2] . In order to prevent such side effects, atropine is used to treat bradycardia with heartbeat rates below 50 beats/min [3, 4] . In our patient, atropine was injected intravenously when the patient's heart rate was between 42-45 beats/min, although the blood pressure was stable. Atropine, a potent cardiac parasympatholytic blocking agent, increases the heart rate and is widely used to treat bradycardia. There are three distinct phases of atropine action on the heart, which include an initial vagotonic effect, a transient period of vagal imbalance at different levels of the conduction system, and a final prolonged period of parasympathetic blockage [5] .
The influence of atropine on the autonomic nervous system which controls the heart is studied via spectral analysis of the heart rate variability (HRV). The spectral analysis of the HRV can distinguish the parasympathetic from the sympathetic influence to the heart. The low frequency (LF) component of the spectral HRV reflects the sympathetic activity with some influence from the vagal activity, whereas the high frequency (HF) component is almost exclusively mediated by the vagal activity. The LF/HF ratio has been used as an index for the sympathovagal balance of the heart, with its increase suggesting sympathetic predominance as a result of increased sympathetic or decreased parasympathetic drive to the heart, or a combination of both [6] . In a report of atropine-induced ventri cular tachycardia, atropine is thought to initially decrease para sym pathetic activity and then provoke unopposed sympathetic activity [7] . This enhanced sympathetic activity pro bably con tributed to the provocation of the coronary artery spasm in our case.
The coronary arteries are innervated by both sympathetic and parasympathetic neurons, and alterations to either nervous system may cause coronary artery spasms. There are many factors involved in the occurrence of perioperative coronary artery spasms -activated sympathetic activity, activated parasympathetic activity, alkalosis, and calcium drugs, etc. Spinal anesthesia by itself can be the cause of coronary artery spasms. It has been shown that a spinal or extradural blockade denervates the sympathetic nervous system by two to three segments above the level of the somatic block. Above the level of the sympathetic blockade, compensatory vasoconstriction is observed, presumably in an effort to offset the reduction in the peri pheral resistance caused by the block. This sympathetic activity reflex involves the cardiac sympathetic nerves causing coronary vasoconstriction and the consequent ischemia [8] . It is likely, in this current case, that a combination of an activated sympathetic nervous system by atropine and spinal anesthesia may be responsible for the coronary artery spasm. Therefore, anesthesiologists should be aware that atropine may provoke coronary artery spasms, especially during spinal anesthesia.
There are some reports of ventricular tachycardia that are induced by atropine in the presence of significant ischemic heart disease [9, 10] . These reports warned of the side effects of atropine administration in patients with ischemic myocardium. In this case, an absence of a preoperative diagnosis of ischemic heart disease (IHD) allowed us to administer atropine. However, as postoperative evaluation showed that the results suggested IHD, the suscep tibility to coronary spasms through atropine may be relatively high for this patient.
Although there are currently no established guidelines for the treatment of bradycardia, it is widely believed that a heart rate below 50 beats per minute after the induction of SA requires treatment. However, further considerations should be taken in regards to the benefits found from the use of atropine in bradycardia, which is not accompanied by hypotension. As in this case, administration of atropine in patients with previously undiagnosed IHD may cause adverse outcomes, such as coronary spasms or ventricular arrhythmia. Therefore, it appears that the administration of atropine should be used with caution and on a flexible basis when bradycardia without hypotension occurs after SA during clinical practice.
